



2nd

Immunology Workshop for Clinicians

PANCRETAN
HEALTH
ASSOCIATION



1-3 November 2019, Heraklion Crete, Aquila Atlantis Hotel

μ


anti-TNF

μ

μ

•

•



Selmaj K et al. Ann Neurol 1991; 30(5):694-700.

•

•

μ

μ

μ

•

-
-
-

μ
(MS)

μ

•

- Guillain– Barre'
- Miller Fisher
- (CIDP)
-
-

μ

μ

μ

μ

•

•

•

29

•

5

•

anti-TNFa

4

•

μ

μ anti-

TNFa

•

μ

μ

•

•

•

μ

MRI

•

MS

•

anti-TNFα,

MS

•

•

μ

anti-IL17

•

MS μ

•

•

- 54
- . Crohn 20 μ
- anti-TNFa 3 LDA
- μ
- μ MRI

•

•

- anti-TNF α

-

μ

-

μ

-

anti-IL 12/23

-

-

Articles

TNF neutralization in MS

Results of a randomized, placebo-controlled multicenter study

The Lenercept Multiple Sclerosis Study Group and The University of British Columbia
MS/MRI Analysis Group*

Table 4 Number, duration, and annual rate of exacerbations during the lenercept MS trial

Exacerbations	Placebo, n = 43	Lenercept, mg			<i>p</i> Value
		10, n = 44	50, n = 40	100, n = 40	
Patients with at least one exacerbation through week 24, n	15	21	28	27	0.003*
Patients with at least one exacerbation through week 48, n	22	26	32	32	0.007†
Exacerbations with onset ≤ week 24	22	28	37	33	
Duration (days) of these exacerbations, mean	28.3	38.6	41.6	42.0	0.62‡
Median (range)	28 (1–91)	31 (6–189)	31 (6–201)	25 (4–261)	
Annualized exacerbation rate	0.98	1.00	1.64	1.47	

* Chi-square tests: global.

† Kruskal-Wallis test.

‡ Kaplan-Meier (KM) (means and medians are estimated from the KM curves).

Table 3 MRI measurements over the first 24 weeks of the lenercept MS trial

Variable	Placebo, n = 43	Lenercept, mg			<i>p</i> Value
		10, n = 44	50, n = 40	100, n = 40	
Newly active lesions, mean	8.9	8.2	15.5	12.0	0.43*
Median (range)	4.0 (0–92)	3.0 (0–55)	5.5 (0–124)	4.5 (0–102)	
Persistently active lesions, mean	6.2	3.3	9.6	3.3	0.36*
Median (range)	1.0 (0–100)	1.0 (0–49)	1.0 (0–128)	1.0 (0–24)	
Percent of active scans, † mean	45.6	40.6	51.6	49.2	0.58†
Median (range)	50 (0–100)	33 (0–100)	50 (0–100)	55 (0–100)	
Percent change in burden of disease, † mean	6.0	9.9	4.3	4.9	0.74†
Median (range)	-2.2 (-28.8–280.9)	0.0 (-30.5–251.0)	1.4 (-35.2–62.8)	-0.2 (-36.0–81.4)	

* Analysis of variance of $\ln(1 + x)$.

† Kruskal-Wallis test.

Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review

María Cruz Fernández-Espartero, MD,* Beatriz Pérez-Zafrilla, BSc,^{†,‡}

Antonio Naranjo, MD,[§] Carmen Esteban, MD,[¶]

Ana M. Ortiz, MD, PhD,^{||} Juan J. Gómez-Reino, MD, PhD,**

Loreto Carmona, MD, PhD,**,^{††} and the BIOBADASER Study Group

- 9256 , 21425 -
- 13 CNS, 1 Guillain– Barre', 22 PNS
- 9 RA ,5 SpA
- 0,65/1000 -
- 51 , 2:1

•

•

Downloaded from <http://ard.bmj.com/> on January 21, 2016 - Published by group.bmj.com



Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry

L Dreyer, M Magyari, B Laursen, R Cordtz, F Sellebjerg and H Locht

Ann Rheum Dis published online December 23, 2015

- 113.527 - μ μ μ
- 12 MS, 47,6 μ
- 8 anti-TNFa
 - 2 , 5 SpA 1
 - 5 , 3
- 4 anti-TNFa
 - 2 , 1 SpA 1
 - 1 , 3
- μ anti-TNFa (SIR 3.48; 95% CI 1.45-8.37) AS (SIR 3.91; 95% CI 1.47-10.2)
- •

11TH INTERNATIONAL CONGRESS ON SPONDYLOARTHRITIDES

4 - 6 October 2018
Gent, Belgium

www.spa-congress.org

Demyelination associated with anti-TNF α treatment in spondyloarthritis patients-A single-center experience





	Gender	Age	Diagnosis	Treatment	Treatment duration (months)	Disease activity	Outcome
Case 1	F	52	Axial SpA/ Crohn	INF	36	LDA	MS
Case 2	M	53	Axial SpA	ETN	22	Remission	MS
Case 3	F	52	Peripheral SpA/psoriasis	ETN (INF, ADA)	120	LDA	MS
Case 4	F	62	Axial SpA/ Crohn	INF	3	LDA	Transverse myelitis
Case 5	F	54	Axial SpA/ Crohn	ADA	46	LDA	MS
Case 6	F	33	Axial SpA/ Crohn	GOL (ADA)	40	LDA	Transverse myelitis
Case 7	F	51	Peripheral SpA/psoriasis	INF	11	LDA	MS
Case 8	F	29	Axial SpA/psoriasis	ADA	4	Remission	MS
Case 9	M	67	Axial SpA/ Crohn	ADA	5	Remission	MS like

μ

- μ anti-TNFα μ
- μ μ ;
- μ MS μ ;
- / μ μ ;

•

•